[ ImCheck Therapeutics raises $21.81M in Series A ]

ImCheck Therapeutics has raised $21.81 million in Series A funding.

Founded in 2015, ImCheck Therapeutics  is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators with a highly differentiated & diversified portfolio of first-in-class therapeutic antibodies in cancers and auto-immunity.

The company intends to use the funds to advance its development plan of several drug-candidates and entry into the clinic by 2019.

Funding  Series A
Founded  2015
Country  France
City  Marseille
Founder / CEO  Benjamin CHARLES
Deal Size  $21.81M
Investors  Gimv
 Kurma Life Science Partners
 Idinvest Partners
 Boehringer Ingelheim Venture  Fund
Previous Investors  /

[adyen action=”checkout_button”]